Kamada Plans Three More Biosimilar Launches In Israel
Post Approval, Company Expects Sales Of $5m-$7m From The Candidates
Israeli firm Kamada has entered into two agreements for commercialization of three biosimilars in Israel. The company expects to launch the products between 2022 and 2024.
You may also be interested in...
Following on from its initial 2019 alliance, Israel’s Kamada has added a further two biosimilar products to its local distribution agreement with Alvotech. The firm’s CEO discussed its planned foray into the biosimilar space as part of a letter to shareholders.
Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.